Evidence map›Paper›PMID 36331777›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Development of Antibody-Based Therapeutics Against West Nile Virus in Plants.

Haiyan Sun, Josh Lesio, Qiang Chen

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Haiyan SunThe Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Josh LesioThe Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Qiang ChenThe Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ, USA. qiang.chen.4@asu.edu.

Funding

Plant-derived MAb therapeutics for west nile virusU01AI075549 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CHEN, QIANG · 2007 to 2010
$1.6M
Bifunctional antibodies with targeted CNS delivery against West Nile VirusR33AI101329 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CHEN, QIANG · 2014 to 2016
$1.3M
NIAID NIH HHS R33 AI101329NIAID NIH HHS U01 AI075549
6 · The paper itself

Abstract

Since its discovery in 1937 in the West Nile district of Uganda, West Nile virus (WNV) has been one of the leading causes of mosquito-transmitted infectious diseases (Smithburn, Burke, Am J Trop Med 20:22, 1940). Subsequently, it spread to Europe, Asia, Australia, and finally North America in 1999 (Sejvar, Ochsner 5(3):6-10, 2003). Worldwide outbreaks have continued to increase since the 1990s (Chancey et al, Biomed Res Int 2015:376230, 2015). According to the Center for Disease Control and Prevention, more than 51,000 cases of WNV infection and nearly 2400 cases of WNV-related death were reported in the USA from 1999 to 2019. The estimated economic impact of WNV infections is close to 800 million dollars in the USA from 1999 to 2012 (Barrett, Am J Trop Med Hyg 90:389, 2014).

Indexed as

CulicidaeWest Nile FeverWest Nile virusAnimalsAntibodiesDisease OutbreaksEuropeAntibodiesMonoclonal antibody (mAb)Plant-derived antibodyPlant expression systemPlant-made biologicsWest Nile virus

Identifiers

PMID36331777
PMCPMC12885604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.